Recode

Award-winning journalist and author Kara Swisher will explain how to navigate today's tech landscape at CompTIA ChannelCon 2024

Retrieved on: 
Tuesday, April 9, 2024
Information technology, BizTech, CompTIA, Education, Knowledge, CNN, Recode, Workforce, Cryptocurrency

DOWNERS GROVE, Ill., April 9, 2024 /PRNewswire/ -- Get ready to be electrified by a keynote session featuring award-winning tech journalist and best-selling author Kara Swisher at CompTIA ChannelCon 2024. Swisher is the host of On with Kara Swisher and co-host of the Pivot podcast with Scott Galloway. She is editor-at-large at New York Magazine, and co-founder of the technology website Recode, and tech conference Code, the country's premier conference on tech and media. Swisher is also a contributor for CNN.

Key Points: 
  • Keynote address will offer insight from Swisher's new book, "Burn Book: A Tech Love Story"
    DOWNERS GROVE, Ill., April 9, 2024 /PRNewswire/ -- Get ready to be electrified by a keynote session featuring award-winning tech journalist and best-selling author Kara Swisher at CompTIA ChannelCon 2024.
  • Swisher is the host of On with Kara Swisher and co-host of the Pivot podcast with Scott Galloway.
  • She is editor-at-large at New York Magazine, and co-founder of the technology website Recode, and tech conference Code, the country's premier conference on tech and media.
  • She will discuss the evolving tech landscape, the role of big tech companies, and the challenges and opportunities that lie ahead.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, February 22, 2024
Research, Intellia Therapeutics, Regeneron Pharmaceuticals, Fatigue, Haemophilia, NK, CTA, Liver, Cystic fibrosis, ATM, A1AT, Amyloidosis, HAE, Therapy, European Medicines Agency, ATTR, Haemophilia B, DNA, European Commission, Hereditary angioedema, Recode, Conference, Cardiomyopathy, AATD, Civil service commission, Clinical trial, Facial muscles, CRISPR, Gene editing, Food, NTLA, KLKB1, Lung, NEJM, TTR, Patient, Medicine, Disease, Tissue, Pharmaceutical industry

Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.

Key Points: 
  • Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.
  • R&D Expenses: Research and development expenses increased by $9.0 million to $109.0 million during the fourth quarter of 2023, compared to $100.0 million during the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $5.4 million to $29.0 million during the fourth quarter of 2023, compared to $23.6 million during the fourth quarter of 2022.
  • Net Loss: The Company’s net loss was $132.2 million for the fourth quarter of 2023, compared to $113.4 million during the fourth quarter of 2022.

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, February 21, 2024
Research, FDA, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, Therapy, LNP, Investigational New Drug, Messenger, Recode, Cystic fibrosis, Food, Cell, Safety, Patient, Disease, IND, Trial of the century, Vaccine

“While progress has been made for many people with CF, those who do not benefit from existing modulators report feeling left behind and continue to face profound physical and emotional hardship from the disease.

Key Points: 
  • “While progress has been made for many people with CF, those who do not benefit from existing modulators report feeling left behind and continue to face profound physical and emotional hardship from the disease.
  • The Phase 1 double-blind, placebo-controlled, first-in-human study is designed to assess the safety and tolerability of a single ascending dose of inhaled RCT2100 administered via nebulizer.
  • The study is being conducted in New Zealand and ReCode anticipates enrolling approximately 32 healthy adults who will receive a single dose of either placebo or RCT2100.
  • ReCode plans to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for a Phase 1 trial of RCT2100 in CF patients in the first half of 2024.

ReCode Therapeutics to Participate in February Conferences

Retrieved on: 
Tuesday, February 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Therapy, Messenger, Recode

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming February conferences:

Key Points: 

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming February conferences:

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Therapy, LNP, Liver, MB, CRISPR, Gene editing, Messenger, Intellia Therapeutics, Recode, Cystic fibrosis, Mucus, NTLA, Lung, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, Research, DNA, Vaccine

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Therapy, LNP, Liver, MB, CRISPR, Gene editing, Intellia Therapeutics, Messenger, Recode, Cystic fibrosis, Mucus, NTLA, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, DNA, Vaccine

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

A Clinically Proven Alzheimer's Treatment Revealed in a Groundbreaking Documentary Narrated by Michael Bublé

Retrieved on: 
Tuesday, February 13, 2024
Amazon Prime Video, Dementia, Memory, Recode, Grammy Awards, Apple TV, Narration, Vimeo, Big Pharma, NHK, Medicine, Patient, Cognition, Clinical trial, Life, Research

BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?

Key Points: 
  • BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?
  • Dr. Bredesen currently has a larger, randomized controlled clinical trial underway that is recruiting patients from six locations across the US.
  • Patients following the Bredesen Protocol and Dr Bredesen's ReCODE Program were profiled in the new documentary film, Memories for Life - Reversing Alzheimer's, which is narrated by Grammy-winner Michael Bublé.
  • The film was initially produced for NHK in Japan, where it originally aired, with additional filming, editing, and narration from Michael Bublé included for the North American market.

Kara Swisher to receive CJF Tribute Award

Retrieved on: 
Wednesday, January 17, 2024
Managing editor, Recode, The Washington Post, CJF, Culture, Pivot, History, Fairmont Royal York, All Things Digital, Canadian Journalism Foundation, Blog, The New York Times, CTV, Tribute, All, Human, NEWS, Nieman Fellowship

TORONTO, Jan. 17, 2024 /CNW/ - The Canadian Journalism Foundation (CJF) is delighted to announce it will honour media icon Kara Swisher with its annual CJF Tribute, in recognition of her trailblazing journalism career, fearlessly speaking truth to power within the technology industry.

Key Points: 
  • TORONTO, Jan. 17, 2024 /CNW/ - The Canadian Journalism Foundation (CJF) is delighted to announce it will honour media icon Kara Swisher with its annual CJF Tribute, in recognition of her trailblazing journalism career, fearlessly speaking truth to power within the technology industry.
  • The annual CJF Tribute recognizes media luminaries who have made an exceptional journalistic impact on the international stage.
  • The Tribute will be presented at the CJF annual Awards evening on June 12 at the Fairmont Royal York in Toronto.
  • The CJF will provide a copy to all attendees at the CJF Awards evening.

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, LNP, Quality of life, DNAI1, Virus, Messenger, FDA, PCD, Cilium, Disease, MBA, Bacteria, Recode, Therapy, Mucus, Volunteering, Patient, Diagnosis, Safety, Primary ciliary dyskinesia, DSM-IV codes, Disorder, Vaccine

“This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.

Key Points: 
  • “This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
  • “This study will evaluate RCT1100 as a potential novel treatment option for patients who do not have any approved therapies.
  • The DNAI1 mRNA is intended to establish or restore proper ciliary function by addressing the underlying cause of the disease.
  • This study brings us one step closer to improving the respiratory health and quality of life of people living with this disease.”

Studies: Promising Cognitive and Imaging Results in Alzheimer’s and pre-dementia Patients

Retrieved on: 
Tuesday, November 21, 2023
Quality of life, Clutch (eggs), Cognition, Dementia, Attention, Medicine, Grammatical mood, Diet, White matter, Systems biology, Incidence, SAN, Recode, JAD, University, San Francisco Bay Area, Medicare, Worldwide, Bangladesh Technical Education Board, Patient, Memory, Curriculum, Journal, Hearing, Exercise

Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.

Key Points: 
  • Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.
  • They also saw physical brain improvements in the imaging results that showed a trend toward renormalization to results typically seen in healthy older adults.
  • While the imaging results appear to correspond with the cognitive assessment results, due to the small sample size and correction for multiple comparisons, the imaging results were not significant.
  • “These are promising and exciting results,” said Dr. Henry Mahncke , CEO of Posit Science.